NAC-1, a potential stem cell pluripotency factor, contributes to paclitaxel resistance in ovarian cancer through inactivating Gadd45 pathway

Oncogene

Volumn 28, Issue 18, 2009, Pages 1941-1948

  Jinawath, N ^a   Vasoontara, C ^a   Yap, K L ^a   Thiaville, M M ^a   Nakayama, K ^b   Wang, T L ^a   Shih, I M ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b SHIMANE UNIVERSITY   (Japan)

Author keywords

Chemoresistance; NAC 1; Ovarian; Paclitaxel

Indexed keywords

CARBOPLATIN; COMPLEMENTARY DNA; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; NUCLEUS ACCUMBENS 1 PROTEIN; PACLITAXEL; RETROVIRUS VECTOR; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BTBD14B PROTEIN, HUMAN; MESSENGER RNA; REPRESSOR PROTEIN; SIGNAL PEPTIDE; TUMOR PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL VIABILITY; CONTROLLED STUDY; DRUG SENSITIVITY; GENETIC TRANSFECTION; HELA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; OVARY CANCER; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; FEMALE; GENETICS; IC 50; METABOLISM; OVARY TUMOR; TUMOR CELL LINE;

POXVIRIDAE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HELA CELLS; HUMANS; INHIBITORY CONCENTRATION 50; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PACLITAXEL; REPRESSOR PROTEINS; RNA, MESSENGER;

EID: 66149110040     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.37     Document Type: Article

References (45)

1. Abeysinghe H.R, Cedrone E, Tyan T, Xu J, Wang N. (1999). Amplification of C-MYC as the origin of the homogeneous staining region in ovarian carcinoma detected by micro-FISH. Cancer Genet Cytogenet 114: 136-143.
2. Abhiman S, Iyer LM, Aravind L. (2008). BEN: a novel domain in chromatin factors and DNA viral proteins. Bioinformatics 24: 458-461.
3. Baker VV, Borst MP, Dixon D, Hatch KD, Shingleton HM, Miller D. (1990). c-myc amplification in ovarian cancer. Gynecol Oncol 38: 340-342.
4. Bourguignon LY, Peyrollier K, Xia W, Gilad E. (2008). Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 283: 17635-17651.
5. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP et al. (2005). Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 122: 947-956.
6. Cha XY, Pierce RC, Kalivas PW, Mackler SA. (1997). NAC-1, a rat brain mRNA, is increased in the nucleus accumbens three weeks after chronic cocaine self-administration. J Neurosci 17: 6864-6871.
7. Chung HK, Yi YW, Jung NC, Kim D, Suh JM, Kim H et al. (2003). CR6-interacting factor 1 interacts with Gadd45 family proteins and modulates the cell cycle. J Biol Chem 278: 28079-28088.
8. Davidson B, Berner A, Trope CG, Wang TL, Shih Ie M. (2007). Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions. Hum Pathol 38: 1030-1036.
9. De Smaele E, Zazzeroni F, Papa S, Nguyen DU, Jin R., Jones J et al. (2001). Induction of gadd45beta by NF-kappaB downregulates pro-apoptotic JNK signalling. Nature 414: 308-313.
10. Dimova I, Raitcheva S, Dimitrov R, Doganov N, Toncheva D. (2006). Correlations between c-myc gene copy-number and clinicopatho-logical parameters of ovarian tumours. Eur J Cancer 42: 674-679.
11. Duan Z, Duan Y, Lamendola DE, Yusuf RZ, Naeem R, Penson RT et al. (2003). Overexpression of MAGE/GAGE genes in paclitaxel/ doxorubicin-resistant human cancer cell lines. Clin Cancer Res 9: 2778-2785.
12. Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, Vaidya A et al. (2006a). Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res 12: 5055-5063.
13. Duan Z, Foster R, Brakora KA, Yusuf RZ, Seiden MV. (2006b). GBP1 overexpression is associated with a paclitaxel resistance phenotype. Cancer Chemother Pharmacol 57: 25-33.
14. Holloway RW, Mehta RS, Finkler NJ, Li KT, McLaren CE, Parker RJ et al. (2002). Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol 87: 8-16.
15. Ishibashi M, Nakayama K, Yeasmin S, Katagiri A, Iida K, Nakayama N et al. (2008). A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer. Clin Cancer Res 14: 3149-3155.
16. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. (2007). Cancer statistics, 2007. CA Cancer J Clin 57: 43-66.
17. Kalivas PW, Duffy P, Mackler SA. (1999). Interrupted expression of NAC-1 augments the behavioral responses to cocaine. Synapse 33: 153-159.
18. Kim J, Chu J, Shen X, Wang J, Orkin SH. (2008). An extended transcriptional network for pluripotency of embryonic stem cells. Cell 132: 1049-1061.
19. Koob G.F. (1996). Drug addiction: the yin and yang of hedonic homeostasis. Neuron 16: 893-896.
20. Korutla L, Degnan R, Wang P, Mackler SA. (2007). NAC1, a cocaine-regulated POZ/BTB protein interacts with CoREST. J Neurochem 101: 611-618.
21. Korutla L, Wang PJ, Mackler SA. (2005). The POZ/BTB protein NAC1 interacts with two different histone deacetylases in neuronal-like cultures. J Neurochem 94: 786-793.
22. Liu GH, Wang SR, Wang B, Kong BH. (2006). Inhibition of nuclear factor-kappaB by an antioxidant enhances paclitaxel sensitivity in ovarian carcinoma cell line. Int J Gynecol Cancer 16: 1777-1782.
23. Loizzi V, Chan JK, Osann K, Cappuccini F, DiSaia PJ, Berman ML. (2003). Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am J Obstet Gynecol 189: 1301-1307.
24. Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T et al. (2004). Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem 279: 23477-23485.
25. Mackler S, Pacchioni A, Degnan R, Homan Y, Conti AC., Kalivas P et al. (2008). Requirement for the POZ/BTB protein NAC1 in acute but not chronic psychomotor stimulant response. Behav Brain Res 187: 48-55.
26. Mackler SA, Korutla L, Cha XY, Koebbe MJ, Fournier KM, Bowers MS et al. (2000). NAC-1 is a brain POZ/BTB protein that can prevent cocaine-induced sensitization in the rat. J Neurosci 20: 6210-6217.
27. Mao TL, Hsu CY, Yen MJ, Gilks B, Sheu JJ, Gabrielson E et al. (2006). Expression of Rsf-1, a chroma tin-remodeling gene, in ovarian and breast carcinoma. Hum Pathol 37: 1169-1175.
28. Materna V, Surowiak P, Kaplenko I, Spaczynski M, Duan Z, Zabel M et al. (2007). Taxol-resistance-associated gene-3 (TRAG-3/CSAG2)
29. expression is predictive for clinical outcome in ovarian carcinoma patients. Virchows Arch 450: 187-194.
30. Muller FJ, Laurent LC, Kostka D, Ulitsky I, Williams R, Lu C et al. (2008). Regulatory networks define phenotypic classes of human stem cell lines. Nature 455: 401-405.
31. Nakayama K, Nakayama N, Davidson B, Katabuchi H, Kurman RJ, Velculescu VE et al. (2006a). Homozygous deletion of MKK4 in ovarian serous carcinoma. Cancer Biol Ther 5: 630-634.
32. Nakayama K, Nakayama N, Davidson B, Sheu JJ, Jinawath N, Santillan A et al. (2006b). A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Natl Acad Sci USA 103: 18739-18744.
33. Nakayama K, Nakayama N, Wang T-L, Shih I-M. (2007). NAC-1 controls cell growth and survival by repressing transcription of Gadd45GIP1, a candidate tumor suppressor. Cancer Res 67: 8058-8064.
34. Qiu W, Zhou B, Zou H, Liu X, Chu PG, Lopez R et al. (2004). Hypermethylation of growth arrest DNA damage-inducible gene 45 beta promoter in human hepatocellular carcinoma. Am J Pathol 165: 1689-1699.
35. Shih Ie M, Sheu JJ, Santillan A, Nakayama K, Yen MJ, Bristow RE et al. (2005). Amplification of a chromatin remodeling gene, Rsf-1/ HBXAP, in ovarian carcinoma. Proc Natl Acad Sci USA 102: 14004-14009.
36. Tang G, Minemoto Y, Dibling B, Purcell NH, Li Z, Karin M et al. (2001). Inhibition of JNK activation through NF-kappaB target genes. Nature 414: 313-317.
37. Verheij M, Bose R, Lin XH, Yao B, Jarvis WD, Grant S et al. (1996). Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 380: 75-79.
38. Wang J, Rao S, Chu J, Shen X, Levasseur DN, Theunissen TW et al. (2006). A protein interaction network for pluripotency of embryonic stem cells. Nature 444: 364-368.
39. Yeasmin S, Nakayama K, Ishibashi M, Katagiri A, Iida K, Purwana IN et al. (2008). Expression of the bric-a-brac tramtrack broad complex protein NAC-1 in cervical carcinomas seems to correlate with poorer prognosis. Clin Cancer Res 14: 1686-1691.
40. Ying J, Srivastava G, Hsieh WS, Gao Z, Murray P, Liao SK et al. (2005). The stress-responsive gene GADD45G is a functional tumor suppressor, with its response to environmental stresses frequently disrupted epigenetically in multiple tumors. Clin Cancer Res 11: 6442-6449.
41. Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV. (2003). Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 3: 1-19.
42. Zerbini LF, Libermann TA. (2005a). GADD45 deregulation in cancer: frequently methylated tumor suppressors and potential therapeutic targets. Clin Cancer Res 11: 6409-6413.
43. Zerbini LF, Libermann TA. (2005b). Life and death in cancer. GADD45 alpha and gamma are critical regulators of NF-kappaB mediated escape from programmed cell death. Cell Cycle 4: 18-20.
44. Zerbini LF, Wang Y, Czibere A, Correa RG, Cho JY, Ijiri K et al. (2004). NF-kappa B-mediated repression of growth arrest- and DNA-damage-inducible proteins 45alpha and gamma is essential for cancer cell survival. Proc Natl Acad Sci USA 101: 13618-13623.
45. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM et al. (2008). Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68: 4311-4320.